Opening
a new frontier
in pharmacology
Opening
a new frontier
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
”
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
“
Pier Vincenzo Piazza, CEO
Latest News
Latest News
Aelis Farma obtains regulatory approval of the Phase 2B trial with AEF0217 in people with Down syndrome
December 2025
+
Final Phase 2B Results with AEF0117 in Cannabis Use Disorder (CUD)
March 2025
+
Aelis Farma
Aelis Farma Headquarter
1 rue Lafaurie de Monbadon
33 000 Bordeaux - France
Aelis Farma Lab Facility
IECB
2 rue Robert Escarpit
33607 Pessac - France
Tel: +33 (0)5 54 54 23 27
contact@aelisfarma.com
This website is co-financed by
the European Union and the New Aquitaine Region.
the European Union and the New Aquitaine Region.
L’Europe s’engage en Nouvelle Aquitaine avec
les Fonds Européens de Développement Régional.
les Fonds Européens de Développement Régional.